Under the terms of the agreement, Cleveland Clinic will investigate whether Pure EP can address common limitations of signal processing, according to an Oct. 25 BioSig news release.
“As a nonprofit, research, education and healthcare institution, Cleveland Clinic has a long legacy of innovation in cardiovascular disease, and specifically in the field of electrophysiology,” BioSig Chief Commercialization Officer Gray Fleming said. “At BioSig, we embody their commitment to clinical discovery and ensuring that optimal treatments are made available to patients with efficiency and efficacy.”
